The investigational trial is designed to assess the safety and efficacy of CD07805/47.
The results demonstrated that CD07805/47 was effective in reducing facial redness.
The trial also showed that during the eight-week study of treatment and follow-up phases topical gel was evaluated as safe and well-tolerated.
University of Louisville Dermatology clinical professor and study principal investigator Joseph Fowler said the results of this study confirm CD07805/47’s potential to become a viable topical treatment option that could possibly help enhance the quality of life for the millions of patients affected by the persistent facial redness of rosacea.